Vanzacaftor

• CAT Number: I045090
• CAS Number: 2374124-49-7
• Molecular Formula: C32H39N7O4S
• Molecular Weight: 617.76
• Purity: ≥95%
• Synonyms: (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2λ6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one
• IUPAC Name: (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2lambda6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one
• InChI: InChI=1S/C32H39N7O4S/c1-30(2)19-21-5-4-16-33-24-6-3-7-27(34-24)44(41,42)37-29(40)22-8-9-25(35-28(22)38(30)20-21)39-17-10-26(36-39)43-18-11-23-31(12-13-31)32(23)14-15-32/h3,6-10,17,21,23H,4-5,11-16,18-20H2,1-2H3,(H,33,34)(H,37,40)/t21-/m0/s1
• InChIKey: VCSUIBJKYCVWNF-NRFANRHFSA-N
• SMILES: CC1(C[C@@H]2CCCNC3=NC(=CC=C3)S(=O)(=O)NC(=O)C4=C(N1C2)N=C(C=C4)N5C=CC(=N5)OCCC6C7(C68CC8)CC7)C

Vanzacaftor（Cat No.:I045090）is a next-generation CFTR corrector developed for the treatment of cystic fibrosis (CF). It works by stabilizing and enhancing the folding and trafficking of defective CFTR proteins—especially those with the F508del mutation—allowing them to reach the cell surface and function properly. Often studied in combination with CFTR potentiators and other correctors, Vanzacaftor improves chloride transport and reduces mucus buildup in the lungs. Its optimized pharmacokinetics and potency support its use in triple-combination regimens. Vanzacaftor is provided for research into novel CF therapies and epithelial ion transport disorders.